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Abstract
The dengue non-structural 3 (NS3) is a multifunctional protein, containing a serino-protease domain, located at the N-
terminal portion, and helicase, NTPase and RTPase domains present in the C-terminal region. This protein is considered the
main target for CD4+ and CD8+ T cell responses during dengue infection, which may be involved in protection. However,
few studies have been undertaken evaluating the use of this protein as a protective antigen against dengue, as well as other
flavivirus. In the present work, we investigate the protective efficacy of DNA vaccines based on the NS3 protein from DENV2.
Different recombinant plasmids were constructed, encoding either the full-length NS3 protein or only its functional domains
(protease and helicase), fused or not to a signal peptide (t-PA). The recombinant proteins were successfully expressed in
transfected BHK-21 cells, and only plasmids encoding the t-PA signal sequence mediated protein secretion. Balb/c mice
were immunized with the different DNA vaccines and challenged with a lethal dose of DENV2. Most animals immunized
with plasmids encoding the full-length NS3 or the helicase domain survived challenge, regardless of the presence of the t-
PA. However, some mice presented clinical signs of infection with high morbidity (hind leg paralysis and hunched posture),
mainly in animal groups immunized with the DNA vaccines based on the helicase domain. On the other hand, inoculation
with plasmids encoding the protease domain did not induce any protection, since mortality and morbidity rates in these
mouse groups were similar to those detected in the control animals. The cellular immune response was analyzed by
ELISPOT with a specific-CD8+ T cell NS3 peptide. Results revealed that the DNA vaccines based on the full-length protein
induced the production of INF-c, thus suggesting the involvement of this branch of the immune system in the protection.
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Introduction
Dengue is an important public health problem with high rates of
morbidity and mortality in most tropical and subtropical areas of
the world. Currently, there are more than 2.5 billion people at risk
of infection throughout the world. It is estimated that 50–100
million dengue infections occur annually and about 250–500
thousand patients develop the most severe symptoms of the
disease, which can lead to death [1–4].
Dengue is a mosquito-borne disease caused by the dengue virus
(DENV), a member of the Flaviviridae family and Flavivirus genus,
which consists of four closely related but antigenically distinct
serotypes, DENV1-4 [5]. Infection may be asymptomatic or result
in a diversity of illnesses, which ranges from acute febrile dengue
fever (DF) to severe disease forms, including dengue hemorrhagic
fever (DHF) and dengue shock syndrome (DSS) [6–7,4]. In spite of
the cross-reactivity observed among the different serotypes,
infection with one DENV induces long-term protective immunity
only to the same serotype. In fact, several reports suggest that an
inappropriate pre-existing immune response against other sero-
types results in the increase of severe cases of the disease observed
in patients experiencing heterotypic secondary infections [8–12].
The DENV genome is constituted of a single positive RNA
strand of approximately 11 kb, which is translated into a large
polyprotein during virus infection. The polyprotein is processed to
yield three structural proteins, capsid (C), premembrane/mem-
brane (prM/M) and envelope (E), as well as seven non-structural
proteins, NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 [13,5].
The cleavage of this polyprotein, which represents an essential step
for viral replication, is performed by host enzymes and the NS3
viral protease [14–16]. The NS3 is a multifunctional protein of
approximately 69kDa, involved in the polyprotein processing,
RNA capping and RNA replication [5,16–17]. It contains a serine
protease domain within the first 180 amino acids at the N-terminal
portion, while the 1–167 residues seems to be the minimum
sequence required for the proteolytic activity in DENV2 [14,18–
19], which is dependent on the association with the co-factor
NS2B [20,15]. The final two-thirds of NS3 protein, in the C-
terminal region, contain three other enzymatic domains: RNA-
stimulated nucleoside triphosphatase (NTPase), RNA helicase and
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25685RNA 59-triphosphatase (RTPase). The helicase domain unwinds
RNA during viral RNA replication and energy for reaction is
provided by the NTPase activity [21–24]. In addition, the RTPase
activity catalyzes the cleavage of the c-b phosphoric anhydride
bond of 59-triphosphorylated RNA, important for RNA 59-
capping [25].
The development of an effective vaccine against dengue became
a priority for the World Health Organization, due to the
increasing incidence of severe cases of the disease and its large
geographical extension in the world. However, one of the main
obstacles for developing such vaccine is the requirement of
activating a protective immune response against all four DENV
serotypes, without the risk of inducing severe disease [26–28]. The
dengue infection elicits different immune responses towards the
viral proteins. Antibodies are generated mainly against the virus
surface E protein and the secreted NS1 protein [29–31], while the
majority of T-cell epitopes are concentrated within the NS3
protein, the main target for CD4+ and CD8+ T cell response
[12,29,32–33]. Vaccines against flavivirus are generally based on
the E protein, which contains most of the epitopes that elicit
neutralizing antibodies [26,32]. However, this protein may also
induce non-neutralizing antibodies involved in the phenomenon
of antibody-dependent enhancement (ADE) of DENV infection,
which can be associated to the occurrence of increased numbers
of DHF in secondary infections [8,34–35]. Alternatively, some
reports suggest the use of non-structural proteins for dengue
vaccines to overcome such problem [36–38]. The NS1 is also
highly immunogenic and may generate antibodies with comple-
ment fixing activity, probably triggering the lyses of infected cells
which present this protein on its surface [36–37,39]. Nevertheless,
antibodies against the NS1 may also cross-react with human
proteins, which can be associated to some pathological effects of
the dengue infection [40–42]. In contrast, there are only few
studies evaluating the use of the NS3 protein as a protective
antigen against DENV, as well as other virus from the Flaviviridae
family. Immunization with the NS3 from flavivirus, in general,
induced only marginal protection in different animal models [43–
45]. Studies with the NS3 from DENV, in its turn, reported that
mice inoculated with monoclonal antibodies against this protein
showed an increase survival time after virus challenge, although
most of animals died in the end of the experiment [46]. Further
studies suggested that the combination of NS3 with other
flavivirus proteins may have a synergetic effect, leading to the
increase of protection rates against virus challenge [47–48]. On
the other hand, other reports suggested the involvement of an
immune response against the NS3 in the pathogenesis of DHF
[49–51].
Therefore, in the present work we evaluated the potential of the
NS3 as a protective antigen against DENV2 using DNA vaccines.
Different plasmids were constructed encoding the full-length NS3
of DENV2 or only its functional domains (protease or helicase),
fused or not to a signal peptide in order to secret the recombinant
protein to extracellular medium. Balb/c mice were immunized
with these DNA vaccines and challenged with a lethal dose of
DENV2. Inoculation with plasmids encoding the protease domain
did not conferred any protection, while most animals immunized
with vaccines based on the helicase domain or the full-length NS3
protein survived virus infection, although several of them
presented some morbidity after challenge. The induction of a
cellular immune response, with the production of INF-c by CD8+
T cells, was detected in animals inoculated by vaccines containing
the entire NS3 gene. As far as we know, this is the first study
showing protection generated by DNA vaccines based exclusively
on the dengue NS3 protein.
Materials and Methods
Virus and cell lines
The dengue 2 virus strain New Guinea C (NGC DENV2) was
used for cloning sequences encoding the NS3 protein or its
functional domains and for challenge assays. The DENV2 used for
RNA extraction and cloning was propagated in cells of Aedes
albopictus (C6/36) (ATCC, USA) in L15 medium (Sigma, USA),
supplemented with 10% fetal bovine serum (FBS, Invitrogen,
USA). The DENV2 used in challenge assays was obtained from
brains of newborn infected mice and propagated in Vero cells
(ATCC) cultivated in medium 199 with Earle salts (E199, Sigma),
buffered with sodium bicarbonate and supplemented with 10%
FBS. For the detection of in vitro expression of recombinant
proteins, baby hamster kidney cells (BHK-21) (ATCC) were
propagated in Dulbecco’s Modified Eagle Medium (DMEM)
(Invitrogen, USA), supplemented with 5% FBS.
Plasmid constructions
Six plasmids based on the pcDNA3 vector (Invitrogen) were
constructed encoding the full-length NS3 sequence or its
functional domains (protease or helicase). Total RNA from C6/
36 cells infected with DENV2 was extracted with Trizol
(Invitrogen), according to the manufacturer protocol, and used
as template for the synthesis of a cDNA. The reaction was
performed by reverse transcriptase M-MLV (Invitrogen) with a
forward primer, 59-GGG GGA TAT CGA TAG TGG TTG
CGT TG-39, which hybridizes to nucleotides 2422–2437 in the
NGC DENV2 sequence (GenBank M29095). Such cDNA was
then used as template for amplification of different NS3 segments
by PCR using forward and reverse primers (Table 1), containing
EcoRV and XbaI restriction sites, respectively. The PCR was
performed as follows: 2 min at 94uC, followed by 30 cycles of
1 min at 92uC, 1 min at 55uC and 2 min at 72uC, with an
extension step of 5 min at 72uC. The different amplified products
were electrophoresed on a 1% agarose gel, recovered with glass
beads, geneclean (Bio 101, USA), restricted with EcoRV and XbaI,
and ligated to plasmids previously digested with these same
enzymes. The pcDNA3 vector (Invitrogen) was used for
construction of pcNS3, pcNS3H and pcNS3P plasmids, while
the pcTPANS3, pcTPANS3H and pcTPANS3P plasmids were
constructed based on the pcTPA, a modified pcDNA3 vector that
contains the human tissue plasminogen activator (t-PA) signal
sequence [52]. The Escherichia coli, strain DH5a, was transformed
with recombinant plasmids, which were screened by restriction
mapping and confirmed by sequencing (ABI PRISM dye
terminator, Applied Biosystems, USA, performed by the Genomic
Plataform DNA Sequencing, PDTS-Fiocruz). Plasmids were
further isolated and purified by Qiagen Plasmid Giga Kit (Qiagen,
Germany), according to manufacturer’s instruction. DNA con-
centrations were quantified by optical density at 260 nm and the
integrity of plasmids was checked by agarose gel electrophoresis.
Plasmids were suspended in sterile water and stored at 220uC
until use.
Transfection of BHK cells with different plasmids
BHK cells were transiently transfected with recombinant
plasmids or control vectors (pcDNA3 or pcTPA) and fixed or
harvested 24 h after transfections. For detection of recombinant
proteins by immunofluorescence, 2610
4 cells/well were plated in
chamber slides (Nunc, Denmark) with Optimen medium (Invitro-
gen) and transfected with 0.2 mg of each DNA, while for western
blot, 5610
5 cells were plated in 25 cm
2 bottle and transfected with
2 mg of each DNA. Transfections were performed 24 h after cell
DNA Vaccines Based on the Dengue NS3 Protein
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ed by the manufacturer.
Immunofluorescence
Monolayers of transfected cells were washed with 0.1 M
phosphate buffer (PB), pH 7.4, fixed with 4% paraformaldehyde
for 10 min, permeabilized with 0.6% saponin for 10 min and
blocked with 1% bovine serum albumin (BSA) and 0.2% saponin
for 15 min. Cells were then incubated for 1 h at 37uC with a
mouse polyclonal antibody against DENV2 NS3 protein that was
expressed in E. coli, washed tree times with PB and incubated for
1 h at 37uC with fluorescein-conjugated goat anti-mouse IgG
(Southern Biotechnology, USA), diluted 1:100 in PB. After
washing again with PB, slides were mounted with Vectashield
medium (Vector Laboratories Inc., USA) and cells were visualized
in a fluorescence microscope (Nikon Eclipse E600).
Western blotting
Western blotting of transfected whole-cell extracts and culture
supernatants was performed as previously described [38]. Proteins
present in culture supernatants were precipitated by adding 100%
trichloroacetic acid (TCA) to a final concentration of 10% (V/V)
and pellets were washed twice with ice-cooled 70% acetone. Cell
extracts and TCA precipitated proteins were suspended in SDS-
PAGEsamplebuffer[53]andboiledfor5 min.Proteinsweresorted
in SDS-PAGE (12.5% total acrylamide concentration) and
transferred into nitrocellulose membranes. Recombinant proteins
weredetected withmousepolyclonal antibodiesagainst theDENV2
NS3 protein, followed by incubation with rabbit anti-mouse IgG
conjugated to horseradish peroxidase (Southern Biotechnology),
diluted 1:4000. Membranes were developed with the ECL kit
(Amersham Biosciences, UK) and exposed to Kodak X Omat films.
Mouse immunization and virus challenge
Experiments with mice were conducted in compliance with
ethical principles in animal experimentation stated in the Brazilian
College of Animal Experimentation and approved by the Animal
Use Ethical Committee of Fundac ¸a ˜o Oswaldo Cruz (FIOCRUZ)
(approval ID: L-067/08).
Male Balb/c mice, 4 to 6 weeks old, were inoculated by the
intramuscular (i.m.) route with 50 mg of plasmid dissolved in
50 mL of phosphate buffer saline (PBS) in each tibialis posterior
muscles (100 mg/mouse) using 27-gauge needles. Each animal
group (n=10 or n=20) received two doses of one recombinant
plasmid (pcTPANS3, pcTPANS3H, pcTPANS3P, pcNS3,
pcNS3H or pcNS3P) or control vectors (pcTPA or pcDNA3),
given 2 weeks apart. Two weeks after the second DNA dose,
vaccinated and non-immunized animals were challenged with the
mouse brain adapted NGC DENV2. For challenge assays,
animals were anesthetized with a mixture of ketamine-xylazine
[54] and then inoculated by the intracerebral route (i.c.) with
30 mL of NGC DENV2 corresponding to approximately 40
LD50. Mice were monitored for 21 days after challenge,
recording mortality and morbidity, expressed mainly by the
appearance of hind leg paralysis and alterations in spinal column.
Evaluation of different morbidity degrees in each animal group
was performed using a scale ranging from 0 to 3 (0= none, 1=
mild paralyses in one hind leg or alteration of the spinal column
with a small hump, 2= severe paralyses in one hind leg and
alteration of the spinal column with a small hump or severe
paralyses in both hind legs, 3= severe paralyses in both hind legs
and deformed spinal column or death). After 21 days, animals
that survived challenge were sacrificed and blood samples were
collected by cardiac puncture. The protective efficacy of the
DNA immunizations was tested in two or one independent
challenge assays, for inoculations with vaccines encoding the t-PA
signal peptide (pcTPANS3, pcTPANS3H and pcTPANS3P) or
injections with plasmids without this sequence (pcNS3, pcNS3H
and pcNS3P), respectively.
Interferon-c ELISPOT assay
Spleen cells from mice inoculated with the pcTPANS3 or
pcNS3 vaccines, as well as with the control vectors pcDNA3 and
pcTPA, were used in IFN-c ELISPOT test. The assay was
performed with a 9-mer peptide (GYISTRVEM), corresponding
to 298–306 amino acid residues of the DENV2 NS3 protein,
which is an immunodominant T cell epitope in Balb/c mice [55].
Groups of animals (n=6) were immunized with the DNA
Table 1. Primers used for amplifications of different DENV2 NS3 sequences for construction of the different recombinant plasmids.
vector
a primers Amplified region
b Recombinant plasmid
pcTPA 59-GGGGGATATCGCTGGAGTATTGTGGG-39
c protease (4522–5076) pcTPANS3P
59-GGGTCTAGATTACTTTCGAAAAATGTCATC-39
d
59-GGGGATATCAGAAAATTGACCATCATGG-39
c helicase (5077–6375) pcTPANS3H
59-GGGGTCTAGATTACTTTCTTCCAGCTGCA-39
d
59-GGGGGATATCGCTGGAGTATTGTGGG-39
c NS3 (4522–6375) pcTPANS3
59-GGGGTCTAGATTACTTTCTTCCAGCTGCA-39
d
pcDNA3 59-GGGGGATATCATGGCTGGAGTATTGTGGG-39
c protease (4522–5076) pcNS3P
59-GGGTCTAGATTACTTTCGAAAAATGTCATC-39
d
59-GGGGATATCATGAGAAAATTGACCATCATGG-39
c helicase (5077–6375) pcNS3H
59-GGGGTCTAGATTACTTTCTTCCAGCTGCA-39
d
59-GGGGGATATCATGGCTGGAGTATTGTGGG-39
c NS3 (4522–6375) pcNS3
59-GGGGTCTAGATTACTTTCTTCCAGCTGCA-39
d
aVectors used for cloning.
bGenome coordinates [64].
cForward primer (start codon is marked in bold type and EcoRV restriction site is underlined).
dReverse primer (stop codon is marked in bold type and Xba I restriction site is underlined).
doi:10.1371/journal.pone.0025685.t001
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weeks after the first immunization.
The IFN-c ELISPOT mouse set (BD Biosciences) was used in
accordance with the manufacturer’s instruction. Briefly, 96-well
filtration plates were coated overnight at 4uC with 5 mg/mL IFN-c
capture monoclonal antiboby (100 mL, in PBS), followed by
washing and blocking with RPMI-1640 medium (Sigma),
containing 1% L-glutamine and 10% FBS, for 2 hours at room
temperature. Red blood lysed splenocytes (10
6 cells/well) were
added in 100 mL RPMI-1640 with the subsequent addition of
100 mL of the NS3 peptide (final concentration of 10 mg/mL).
Non-stimulated and concanavalin A (Con A, 5 mg/mL) stimulated
cells were used as negative and positive controls, respectively.
Splenocytes were cultured for 20 h at 37uC under 5% CO2. Plates
were washed once with water and then with 0.05% Tween 20-PBS
(PBST), followed by incubation for 2 h at room temperature with
2 mg/mL of biotinylated IFN-c detection antibody, diluted in
100 mL PBS with 10% FBS. Plates were washed again with PBST
and incubated for 1 h at room temperature with streptavidin-
horseradish peroxidase diluted 1:100. Spots were revealed with
AEC substrate reagent set (BD Bioscience) at room temperature
and counted with an Immunospot reader (Cellular Technology
Ltd, Cleveland,OH) using the Immunospot Software Version 3.
Results were expressed as the average of spot-forming cells
number (SFC) per 10
6 cells, from triplicate wells, after subtraction
of background values detected in splenocytes incubated only with
medium.
Statistical analysis
Statistical experimental analyses were performed using the
GraphPad Prism software (La Jolla, USA), version 5.02. For the
analysis of survival rates, statistical significances were evaluated by
chi-square test, while differences in the degree of morbidity and in
SFC values were analyzed by Mann-Whitney test. Values were
considered significant at P,0.05.
Results
Construction of different DNA vaccines based on the NS3
protein or its functional domains
Six DNA vaccines, pcNS3, pcNS3H, pcNS3P, pcTPANS3,
pcTPANS3H and pcTPANS3P, were constructed as described in
materials and methods and represented in figure 1. The pcNS3
and pcTPANS3 vaccines encode the full-length NS3 protein. The
pcNS3P and pcTPANS3P plasmids contain the sequence that
codes the first 185 NS3 N-terminal amino acids, which enclose
the protease domain, while constructs pcNS3H and pcTPANS3H
encode the 433 NS3 C-terminal amino acids (from residues 186
to 618), which correspond to the RTPase/NTPase/helicase
domains. Fragments were cloned without any signal sequence
(pcNS3P, pcNS3H and pcNS3), for intracellular expression, or in
frame with the t-PA signal peptide (pcTPANS3P, pcTPAND3H
and pcTPANS3), for the secretion of recombinant proteins
(Fig. 1).
Figure 1. Schematic representation of the DENV2 genome (a) and the regions coded by the different recombinant plasmids (b):
pcTPANS3, pcTPANS3P, pcTPANS3H, pcNS3, pcNS3P, pcNS3H. Boxes represent the NS3 region (gray areas), the protease domain (streaked
areas) and the helicase/RTPase/NTPase (dotted areas) domain; black box symbolizes the signal peptide derived from the human tissue plasminogen
activator (t-PA).
doi:10.1371/journal.pone.0025685.g001
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The expression of recombinant proteins was evaluated in BHK-
21 cells transiently transfected with the different plasmids.
Immunofluorescence assays revealed positive reaction in cells
transfected with all recombinant plasmids, indicating that
constructs were able to promote expression of the full-length
NS3 protein or its functional domains in eukaryotic systems,
regardless the presence of the t-PA signal peptide (Fig. 2). Cells
transfected with control vectors (pcTPA or pcDNA3) did not react
with NS3-specific antibodies (data not shown). Western blot
analysis of transfected cell extracts confirmed the identity of the
recombinant proteins, showing predictable molecular weights. A
protein of approximately 20 kDa, corresponding to the NS3
protease domain, was detected in pcTPANS3P- and pcNS3P-
transfected cell lysates, while extracts from cells transfected with
pcTPANS3H and pcNS3H revealed a band around 50 kDa,
according to the 433 amino acids of the helicase domain (Fig. 3a).
Furthermore, a band of approximately 70 kDa was observed in
pcTPANS3- and pcNS3-transfected cell extracts, which corre-
sponds to the full-length NS3 protein (Fig. 3a). Other specific
bands, with different molecular weights, were also observed in the
extract of cells transfected with plasmids encoding the full-length
NS3 or the helicase domain, probably resulting from spontaneous
cleavage and/or degradation of the NS3 protein. As expected,
NS3-specific recombinant proteins were detected only in the
supernatants of cells transfected with plasmids containing the t-PA
signal sequence (pcTPANS3P, pcTPANS3H and pcTPANS3),
which demonstrated that this signal peptide indeed targeted the
proteins to secretion (Fig. 3b). No NS3-specific band was observed
in extracts or supernatants of cells transfected with control vectors
(Fig. 3).
Protection generated by the different DNA vaccines
encoding NS3 regions
The protective efficacy of plasmids encoding the full-length NS3
protein or its functional domains was evaluated in mice
immunized with such DNA vaccines and challenged with a mouse
brain-adapted DENV2. Results indicated that the tested vaccines
Figure 2. Immunofluorescence of BHK-21 cells transfected with recombinant plasmids based on NS3 protein or its functional
domains: pcTPANS3 (a), pcTPANS3H (b), pcTPANS3P (c), pcNS3 (d), pcNS3H (e) and pcNS3P (e). Cells were treated with a mouse
polyclonal antibody against the DENV2 NS3 protein. Magnification 400x.
doi:10.1371/journal.pone.0025685.g002
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NS3 region, regardless the presence or not of the signal peptide.
Animals vaccinated with pcTPANS3 presented 90% of survival
rate, while 70% of pcTPANS3H-immunized mice survived virus
challenge, although this difference was not statistically significant
(Fig. 4a). However, both group showed statistically significant
differences of survival rates when compared to control groups, in
which only 25% and 30% of non-immunized and pcTPA-
inoculated animals, respectively, survived virus inoculation
(p,0.0001) (Fig. 4a). Similar results were observed in the mouse
groups inoculated with pcNS3 and pcNS3H plasmids, both
presenting survival rates of 80%, which was statistically different
(p,0.0001) from control animals (20% and 30%, in non-
immunized and pcDNA3-inoculated mice, respectively) (Fig. 4b).
Furthermore, the presence of the t-PA signal sequence in the
constructions encoding either the entire NS3 or the helicase
domain did not induce statistical differences in survival rates, when
compared to results observed with similar plasmids without this
signal peptide. In contrast, none of the DNA vaccines encoding
only the NS3 protease domain induced protection against the
DENV2 challenge, with survival rates of 25% and 30% for
pcTPANS3P- and pcNS3P-immunized mice, respectively, which
was similar to those observed in control groups (Figs. 4a and 4b).
Although most of animals immunized with the DNA vaccines
based in full-length NS3 survived virus challenge, 40% and 60% of
pcTPANS3- and pcNS3-immunized mice, respectively, showed
clinical signs of infection (Fig. 5). In fact, 30% of these animals
manifested severe neurological signs (grades 2 and 3). However,
the morbidity rate in these groups were significant different
comparing to non-immunized mice, in which 95% to 100% of
animals presented several clinical signs of infection (p,0,0001 for
pcTPANS3 and p,0,01 for pcNS3) (Figs. 5a and 5b). In contrast,
75% to 80% of mice inoculated with the vaccines containing the
helicase domain and 90% of animals injected with plasmids based
Figure 4. Survival percentage of Balb/c mice immunized with pcTPANS3, pcTPANS3H and pcTPANS3P (a) or pcNS3, pcNS3H and
pcNS3P (b) and challenged with the NGC DENV2. Mice were immunized with two DNA doses and challenged 4 weeks after the first plasmid
inoculation. Non-immunized (DENV2) and pcTPA or pcDNA3-injected mice followed the same dengue virus infection procedure. Mice were daily
monitored and death was recorded. Data represent compilation of two (a) or one (b) independent experiments, with groups of 10 animals in each
test (n=20 and n=10, respectively).
doi:10.1371/journal.pone.0025685.g004
Figure 3. Western blots of whole-cell extract (a) and culture supernatants (b) of BHK-21 cells transfected with the different DNA
vaccines. The recombinant proteins were detected in SDS-PAGE, using a mouse polyclonal antibody against the DENV2 NS3, harvested from
transfections with pcTPA (lane 1), pcTPANS3P (lane 2), pcTPANS3H (lane 3), pcTPANS3 (lane 4), pcNS3P (lane 5), pcNS3H (lane 6) and pcNS3 (lane 7).
Arrows indicate bands corresponding to the protease, helicase and full-length NS3 recombinant proteins.
doi:10.1371/journal.pone.0025685.g003
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(Fig. 5), and these morbidity degrees were not statistically different
from that observed in non-immunized groups. Furthermore,
results showed that pcTPANS3H-immunized animals presented
statistically higher morbidity degrees when compared to mice
vaccinated with the pcTPANS3 (p,0.04). Thus, data indicated
that only immunization with plasmids based on the full-length
NS3 protein confered some protection, when mortality and
morbidity parameters were taken together.
Production of IFN-c induced by DNA vaccines encoding
the NS3 region
An IFN-c ELISPOT assay was performed in order to
investigate the T-cell response induced with plasmids encoding
the full-length NS3 protein, using a previously identified NS3
immunodominant epitope in Balb/c mice. All animals immunized
with either the pcTPANS3 or pcNS3 DNA vaccines presented
higher and statistically different SFC values when compared to the
control groups, inoculated with pcDNA3 or pcTPA plasmids
(Fig. 6). Overall, animals vaccinated with the pcNS3 presented
higher frequencies of NS3-specific IFN-c-secreting cells comparing
to pcTPANS3-immunized mice, although such differences were
not statistically significant (Fig. 6). Positive control using Con A as
stimulating antigen confirmed the cell viability (data not shown).
Discussion
The NS3 is a conserved protein among the different dengue
serotypes, which elicits a strong cellular immune response after viral
infection inhumansand animalmodels[5,12,29,32].Althoughthere
are several studies analyzing such immune responses, little is known
about the ability of this protein to induce protection. Therefore, in
the present work, we tested different DNA vaccines either encoding
the full-length NS3 protein or only its functional domains, protease
and helicase, in order to evaluate their protective potential in mice.
The DNA vaccines were constructed with or without a signal
peptide for secretion of the antigens. All constructs were able to
mediate the expression of recombinant proteins in vitro, evaluated
in BHK-21 cells transfected with the different plasmids. However,
secretion of NS3, as well as its protease and helicase domains, was
Figure 6. Production of INF-c by T cells of animals immunized
with the DNA vaccines encoding the full-length NS3 protein.
Splenocytes collected from groups of mice (n=6) inoculated with
pcTPANS3, pcNS3, pcDNA3 or pcTPA plasmids were stimulated with a
T-cell specific peptide and the number of spot-forming cells (SFC) were
quantified in a 24h ELISPOT assay. Asterisks indicate statistically
significant differences (**, p,0.003).
doi:10.1371/journal.pone.0025685.g006
Figure 5. Morbidity degree of Balb/c mice inoculated with pcTPANS3, pcTPANS3H, pcTPANS3P and pcTPA (a) or pcNS3, pcNS3H,
pcNS3P and pcDNA3 (b) and challenged with the NGC DENV2. Control groups of non-immunized animals (DENV2) were also challenge with
the dengue virus. Clinical signs of infection, mainly hind leg paralysis, alterations in spinal column and deaths, were monitored during 21 days post
challenge. The semi-quantitative analysis of morbidity degrees after virus challenge were performed using a subjective scale ranging from 0 to 3 (0=
none, 1= mild paralyses in one hind leg or alteration of the spinal column with small bump, 2= one severe hind leg paralyses and alteration of the
spinal column with small bump or two severe hind leg paralyses, 3= two severe hind leg paralyses and bump deformed spinal column or death).
Asterisks indicate statistically significant differences (***, p,0.0001; **, p,0.01; *, p,0.04).
doi:10.1371/journal.pone.0025685.g005
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signal sequence, thus confirming that this peptide was efficient for
targeting translocation of such proteins into the endoplasmic
reticulum and golgi complex. Other reports with different genes,
including those from our group, also used the t-PA signal peptide in
DNA vaccines, in order to mediate the secretion of recombinant
antigens. In these cases, protein secretion seemed to be essential for
the induction of a robust immune response, particularly regarding
the production of antibodies [38,56–58]. Nevertheless, in the
present work, after immunization with plasmids encoding the t-PA
signal sequence, we observed only a weak antibody response against
the NS3, detected in 1/5, 2/5 and 3/5 animals inoculated with
pcTPANS3H, pcTPANS3P and pcTPANS3 DNA vaccines,
respectively, with titers ranging from 200 to 1500 (data not shown).
Such response were of a low magnitude, especially when compared
to DNA vaccines encoding other dengue virus antigens fused to the
t-PA peptide, in which specific antibody titers reached approxi-
mately 30,000 [38,52]. Actually, the NS3 protein seems to be a
weaker inducer of antibody responses after dengue infection
[29,30]. On the other hand, a cellular immune response with the
production of INF-c by CD8+ T cells was observed in mice
immunized with the DNA vaccines encoding the NS3 protein fused
or not with the t-PA sequence. Therefore, secretion of the antigen
does not seem to be essential for the induction of such immune
response, at least in the case of our constructions.
Protection induced by the DNA vaccines encoding the full-length
NS3 protein or its functional domains was evaluated in Balb/c mice
challenged with a lethaldose ofDENV2.Survival rate analysesafter
viral infection showed that plasmids encoding only the protease
domain did not ensure any protection, since results were similar to
those observed in control groups (non-immunized or pcTPA- and
pcDNA3-inoculated animals). In fact, all the challenge experiments
were performed in adult mice, due to the immunization protocol,
and animals at this age are naturally less susceptible to DENV
infection, which may explain the survival rates observed in control
groups. However, severe morbidity was observed in most of these
animals. In contrast, vaccines based on the NS3 complete sequence
or the helicase portion induced high survival rates, regardless of the
t-PA signal peptide presence. Nevertheless, such protection was
partial when we evaluated morbidity in vaccinated mice after the
virus challenge. In this case, several animals presented infection
clinical signs, some of them with high degrees of morbidity.
However, in general, mice immunized with the vaccines encoding
the full-length NS3 protein exhibited less morbidity, concerning
either rates or degrees, when compared to the other groups.
Although the protection observed in our work was not complete, as
far as we know, this is the first report showing that NS3 can, in fact,
induce a protective response against DENV. Young et al. [45]
described a partial protection elicited in calves immunized with a
DNA vaccine encoding the NS3 protein from the bovine viral
diarrhea virus (BVDV), another virus from the Flaviviridae family. In
this study, authors observed that vaccination prevented fever and virus
establishment in the nasal mucosa in 40% of these animals. Konishi et
al. [44], in turn, reported that DNA immunization with a plasmid
containing the NS3 gene from the Japanese encephalitis virus (JEV),
also a flavivirus, elicited protection in 50% of mice challenged with a
relatively low virus dose. However, such results were not reproducible
when a high challenge dose was used. Moreover, studies with one
other flavivirus, employing a DNA vaccine based on the NS3 from the
tick-borne encephalitis virus (TBEV), revealed absence of protection
in mice [43]. On the other hand, the combination of vaccines
encoding NS3 as well as another virus protein seemed to have a
synergic result, increasing protection levels [47–48].
Regarding dengue studies, Tan et al. [46] stated that passive
immunization with monoclonal antibodies against NS3 protracted
the mean time of survival in mice challenged with a lethal dose of
DENV1. However, although the mechanism involved in the
protection elicited by NS3 has not so far been established, the
humoral immune response against this protein probably only plays
a marginal role since it is a non-structural protein mostly present
inside infected cells. Thus, anti-NS3 antibodies would unlikely
have access to this protein and, therefore, would not have a
neutralization activity during virus infection. Nevertheless, after
infection the DENV NS3 elicit antibodies in humans, mainly in
secondary infections, although the predominant humoral immune
response is directed to the E and NS1 proteins [29–31,59], which
seems to contribute to viral clearance [36,39,60–61].
On the other hand, NS3 is an important target for T cell
responses. Studies with DENV infected patients or volunteers
receiving candidate vaccines evidenced CD4+ and CD8+ T-cell
epitopes throughout the entire extension of this protein [12].
Moreover, an epitope for CD8+ T cells was also identified in H-
2K
d-restricted mice (Balb/c), corresponding to amino acids 298–
306 (GYISTRVEM) of DENV2 NS3, which are in the helicase
domain [55]. In accordance with such findings, we observed that
the DNA vaccines encoding the full-length NS3 induced a cellular
immune response against this epitope with the production of INF-c.
Therefore, results suggest the participation of a cellular immune
response in the mechanism of protection induced by the DNA
vaccines based on the NS3 protein. In fact, protection was only
evidenced in animals immunized with the DNA vaccines encoding
eitherthefull-length proteinorthe helicasedomain,both presenting
this immunodominant T cell epitope. In contrast, no protection was
detected in mice inoculated with the DNA vaccines encoding only
the protease domain, which does not contain this epitope.
There is little information about the association of specific T cell
responses and protection against either primary or secondary
DENV infection. Recently, Yauch et al. [62] demonstrated an
important role for CD8+ T cells in the host defense. On the other
hand, activation of memory CD8+ T cells during heterologous
secondary DENV infection appears to result in cytokine storms,
characteristic of DHF/DSS [11,50,63]. Therefore, further studies
will be necessary for the establishment of the mechanisms involved
in the protection induced by the DNA vaccines based on the NS3
protein. The cellular immune response elicited by these vaccines
seems to be important for protection, which probably involves
activation of cytotoxic cells that can destroy infected cells, thus
preventing virus spread. However, the partial protection observed
in challenged animals indicates that such response is not sufficient
and other branch of the immune response should also be activated.
Hence, we cannot exclude the possibility of combining immuniza-
tion with other dengue vaccines, encoding different viral proteins,
which might synergistically increase protective immune responses.
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